Acetylated PEI Polyplexes for Serum-Stable Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene delivery methods face challenges such as high toxicity, limited transfection efficiency, and instability in serum, particularly for immune cells, due to the biomolecule corona and complex formulation requirements, which hinder their in vivo applicability.
Innovation Solution
Development of immunoplexes (IPs) comprising acetylated polyethylenimine (Ac-PEI) complexed with plasmid DNA enveloped within an anionic poly(ethylene-alt-maleic acid) (PEMA) layer, optimizing N/P ratios and surface chemistry to enhance stability and reduce toxicity, enabling serum-independent transfection of immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic polymers like PEI are used for gene delivery, then transfection efficiency is improved, but toxicity increases due to cell membrane damage and apoptosis
Solution Approach 1:
The patent applies parameter changes by modifying the chemical properties of PEI through acetylation to create Ac-PEI. This chemical modification changes the polymer's buffering capacity and reduces its toxicity while maintaining transfection efficiency. The degree of acetylation is optimized to achieve the right balance between efficiency and safety
Solution Approach 2:
The patent creates a composite delivery system by combining Ac-PEI with anionic polymers such as PEMA to form polyplexes. This composite structure leverages the cationic properties of Ac-PEI for DNA binding and transfection efficiency while the anionic polymer component reduces toxicity and improves biocompatibility
2Productivity
If high N/P ratios are used to improve transfection efficiency, then gene delivery effectiveness increases, but toxicity increases through cell membrane damage
Solution Approach 1:
The patent modifies the chemical parameters of the delivery polymer through acetylation, which changes the pKa and buffering capacity. This allows the system to achieve effective transfection at lower N/P ratios, thereby reducing the toxicity associated with high polymer-to-DNA ratios
3Productivity
If physical methods like electroporation are used, then transfection efficiency is improved, but toxicity increases and cell-specific targeting is not achieved
Solution Approach 1:
The patent replaces mechanical physical methods (electroporation, microinjection) with a chemical-based polyplex delivery system. The polyplexes utilize electrostatic interactions and cellular uptake mechanisms rather than external physical forces, thereby achieving transfection without the high toxicity and equipment requirements of physical methods
4Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but safety concerns arise due to mutagenicity and immunogenicity
Solution Approach 1:
The patent employs non-viral polyplex particles as transient, disposable delivery vehicles. These synthetic polymers degrade into harmless byproducts after delivering their cargo, unlike viral vectors that persist and pose long-term safety risks. The polyplexes provide viral-level efficiency without the persistent safety concerns
5Productivity
If conventional polyplex formulations are used, then gene delivery is achieved, but stability in serum is reduced due to biomolecule corona formation
Solution Approach 1:
The patent creates composite polyplex structures combining Ac-PEI with anionic polymers like PEMA. This composite architecture provides a protective interface that reduces unwanted interactions with serum proteins, maintaining particle stability and preventing premature degradation in physiological environments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Immunoplexes demonstrate improved stability, reduced toxicity, and enhanced gene expression in immune cells, offering a simple, modular, and targetable gene delivery platform for efficient transfection of innate and adaptive immune cells in both serum-free and serum-containing conditions.
Implementation Method 1
PEI-based polyplexes are internalized via endosomal/lysosomal trafficking and escape from vesicles by the 'proton-sponge' mechanism
Implementation Method 2
immunoplexes (IPs) that consist of an inner Ac-PEI/pDNA polyplex enveloped within an anionic poly(ethylene-alt-maleic acid) (PEMA) polyelectrolyte layer
Data Source
AI summary
The present invention provides a non-viral polyplex particle for delivering nucleic acid to cells, comprising an effective amount of polyethylenimine complexed with an effective amount of the nucleic acid; and an effective amount of an anionic biomaterial that envelops the complexed acetylated polyethylenimine and nucleic acid.